SIRT1 and breast carcinoma: Doxorubicin-induced SIRT1 promotes redox imbalance and chemoresistance in breast cancer by enhancing cell proliferation, angiogenesis, and metastasis through NRF2 activation and increased glutathione levels (Sahoo et al., 2024).